http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005033051-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6512 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6512 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 |
| filingDate | 2002-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_462432226cd74a066598a7b72162da23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2515fb879836609ac20c983504358cda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_551823b857f08051514c265b1483e730 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a12d82086ac6d1aaeb7cb8c61d54a082 |
| publicationDate | 2005-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005033051-A1 |
| titleOfInvention | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| abstract | Compounds represented by the formula (I) R is H, OH, alkyl, O-alkyl, CH 2 —O-alkyl, (CH 2 )nOH, (CH 2 )nNH 2 , (CH 2 )nCONH 2 , (CH 2 )nOOOH; R 1 is H, OH, alkyl, O-alkyl, CH 2 —O-alkyl, C 6 H 11 , CH 2 OH; R 2 is H, alkyl, OH, CH 2 OH, CH 2 —O-alkyl, CH(OH)-alkyl, CH(OH)CH 2 OH, CH 2 -halogen; R 3 and R 4 independently is H, OH, alkyl; Z is OR 5 , OR 6 , or aminoacids and esters thereof R 5 and R 6 independently is H, alkyl, aryl, pivaloyloxymethyl, C(R 7 ) 2 OC(O) X (R 8 )a formula (II), R 7 independently is —H, C 1 -C 12 alkyl, C 5 -C 12 aryl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 7 -C 12 alkenylaryl, C 7 -C 12 alkynylaryl, or C 6 -C 12 alkaryl, any of which is unsubstituted or is substituted with 1 or 2 halo, cyano, azido, nitro, or —OR 9 ; R 9 is C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl or C 5 -C 12 aryl; provided that at least one R 8 is not H; and a is 1 when X is CH 2 , or direct bond, or 1 or 2 when X is N with the proviso that when a is 2 and X is N, (a) two N-linked R groups can be taken together to form a carbocyclic or oxygen containing heterocycle, (b) one N-linked R 8 additionally can be —OR 9 or (c) both N-linked R 8 groups can be —H; R 10 is H or C 1 -C 8 alkyl; R 11 is selected from H, alkyl, alkenyl, alkynyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl n is 1-5 m is 0 to 5 X is S, N(R 8 ) or direct bond Y is O, S, N (R 8 ), and CHR 1 B is selected from the group consisting of adenine, guanine, cytosine, uracil, thymine, modified purines and pyrimidines such as inosin-9-yl, 2-amino-purin-9-yl, 2amino-6-chloro-purin-9-yl, 2-6-diamino-purin-9-yl, 3-carboxamido-1, 2, 4-triazol-1-yl, 3-deaza-adenin-9-yl, 3-deaza-guanin-9-yl, 3-deaza-inosin-9-yl, 3-deaza-2-amino-purin-9-yl, 3-deaza-2-amino-6-chloro-purin-9-yl, 3-deaza-2, 6-diamino-purin-9-yl, 7-deaza-adenin-9-yl, 7-deaza-guanin-9-yl, 7-deaza-inosin-9-yl, 7-deaza-2-amino-purin-9-yl, 7-deaza-2-amino-6-chloro-purin-9-yl, 7-deaza-2-6-diamino-purin-9-yl, 7-deaza-8-aza-adenin-9-yl, 7-deaza-8-aza-guanin-9-yl, 7-deaza-8-aza-inosnin-9-yl, 7-deaza-8-aza-2-amino-purin-9-yl, 7-deaza-8-aza-2-amino-6-chloro-purin-9-yl, 7-deaza-8-aza-2-6-diamino-purin-9-yl, -8-aza-adenin-9-yl,-8-aza-guanin-9-yl, -8-aza-inosnin-9-yl, -8-aza-2-amino-purin-9-yl, -8-aza-2-amino-6-chloro-purin-9-yl, -8-aza-2-6-diamino-purin-9-yl, 5-aza-thymin-1-yl, 5-aza-cytosin-1-yl, 5-aza-uracil-1-yl, 6-aza-thymin-1-yl, 6-aza-cytosin-1-yl, 6-aza-uracil-1-yl, 2-thiouracil-1-yl, 4-thiouracil-1-yl, 2 thiocytosine-1-yl, uracil-5-yl, 2-thiouracil-5-yl, 4-thiouracil-5-yl, substituted pyridine derivatives such as 6-azauracil, and azacyzosine. In general, attachment may be at different positions in the ring at nitrogen or carbon. These B ring systems may be substituted with halo, alkyl, substituted alkyl (F, Cl, Br, I, OH), NH 2 , N 3 , aryl, substituted aryl (F, Cl, Br, I, OH, NH 2 ), aralkyl; and pharmaceutically acceptable salts thereof and prodrugs thereof are provided. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006122391-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021119500-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7388002-B2 |
| priorityDate | 2001-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 583.